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  The ligand N-phenyl-N'-(2-thiazolyl) thiourea (LH) has been prepared from reaction of phenyl isothiocyanate with  
2-aminothiazol. Treatment of deporotonated ligand (LH) with sodium tetrachloro palladate(II) afforded [Pd(L)2] complex 3. 
Reaction of complex 3 with [bis(diphenylphosphino) methane, dppm], [1,2-bis(diphenylphosphino)ethane, dppe] and  
[1,3-bis(diphenylphosphino)propane, dppp] afforded the mixed ligand complexes of the type [Pd(II)L2(Ph2P(CH2)nPPh2)], {where 
n = 1, dppm, n = 2, dppe or n = 3, dppp) 4-6, respectively. Further, complexes 4-6 have been treated with some transition metal 
salts to give homo- and heterobimetallic complexes 7-21 of the types: [(Ph2P(CH2)nPPh2) Pd (II)-µ-L2M'(II)Xm] and 
[(Ph2P(CH2)nPPh2)Pd(II)-µ-L2M'(II)Xm xH2O] ( where n= 1, 2, or 3 , M' = Pd(II), Ni(II), Mn(II), Co (II) or Cu (II) and  
X = Cl-, m = 2). The ligand and the prepared complexes have been characterized by elemental analysis, molar conductivity, 
magnetic susceptibility, FTIR, UV-Vis, 1H-31P{1H} NMR and mass spectroscopy. Some of these complexes have been assayed for 
their inhibition activity against human rhabdomyosarcoma (RMS) cell line. Interestingly, compound 19 exhibited a significant 
cytotoxicity inhibition activity ~90% for RMS cell line, suggesting being a new lead in the development of human muscle 
anticancer agent. All the compounds have been screened for their antibacterial activity against S. aureus and E. coli bacterium. 
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The palladium (II) as nonplatinum metal complexes 
highly attracted the researchers because of its 
significant biological activity as well as lower side 
effects along with higher lipophilicity or solubility 
compared to cisplatin1-7. Chelating thiourea ligands 
containing N, S and O donor atoms show broad 
biological activity and the existence of metal ions 
bonded to biologically active compounds may 
enhance their activities8-11. 
 
There are several reports describing studies of 
acylthiourea palladium complexes focusing on their 
antimicrobial12, fungicidal13, thermal14 or 
mesomorphic15 properties. Pd (II) complexes are 
preferable metal-based anticancer drugs due to their 
structural and thermodynamic similarities to Pt (II) 
complexes along with the coordination geometry and 
complex forming processes of Pd (II) are closely 
related to those of Pt (II) metal16. Many of the 
prepared palladium (II) complexes showed a discrete 
antitumor activity In vitro compared to the platinum 
based drugs because of their extremely high lability in 
biological fluids17, such as the ionic Pd (II) 
alkyldiphosphine complex 1 (Fig. 1) which caused 
100% tumor cell death at very low concentration  
(< 1.25 μM). It has been reported that palladium 
complexes, e.g. complex 2 (Fig. 1), exhibited 
remarkable antiproliferative activity against some 
cancer cell lines such as MT-4, CD4+ human acute  
T-lymphoblastic leukemia (CCRF-SB) (IC50 = 0.70 ± 
0.05 μM), human splenic B-lymphoblastoid cells, 
human acute B-lymphoblastic leukemia, skin 
melanoma, and prostate carcinoma cell lines18. The 
anticancer activity of palladium complexes has 
 
 
Fig.1 ⸺ Palladium (II) complexes as anticancer agents. 




recently been subject of a detailed review19. On the 
other hand, transition metal complexes with thiourea 
ligands have been extensively investigated for their 
antibacterial, antifungal, antitubercular, antithyroid, 
insecticidal and anticancer properties20-24.  
 
In view of varied pharmacological activities of 
palladium and transition metal complexes, herein we 
report the synthesis and characterization of some new 
palladium (II) complexes of the deprotonated 
thioureas ; mononuclear, homo and heterobimetallic 
complexes of palladium (II) with some transition metal 
ions containing the ligands N-phenyl-N'-(2-
thiazolyl)thiourea and diphosphines Ph2P(CH2)nPPh2 
(where n = 1-3), as well as evaluation of their 
inhibition of rhabdomyosarcoma (RMS) cell line and 
antibacterial activity. 
 
Materials and Methods 
The compounds Na2PdCl4, NiCl2 .6H2O, 
MnCl2.4H2O, CoCl2.6H2O, CuCl2.2H2O, dppm, dppe, 
and dppp were obtained from Fluke and BDH 
Companies. The compounds 2-aminothiazol, and 
Phenyl isothiocyanate, were purchased from Solarbio 
Life Sciences Co. All the chemicals and solvents were 
analytically pure and used without further 
purification. 
Melting points were measured on Electrothermal 
digital melting point apparatus Model 1102D. Micro 
analytical data were obtained with EA 3000 from 
Euro Vector and Perkin Elmer-2400 CHNS 
analyzer31. P and 1H-NMR spectra were recorded on 
Bruker Avance-III 400 MHz, and (13C) NMR spectra 
were recorded on Bruker, Germany instrument. I.R. 
spectra were recorded on a Shimadzu FT-IR 8400 
spectrophotometer using CsI discs. Mass spectrum 
was recorded on Shimadzu GCMS- spectrometer. 
Magnetic measurements were recorded on a Bruker 
BM6 instrument at room temperature using the 
Faraday method. The conductivities of the complexes 
were measured in DMF using Fisher Scientific 
Multimeter Model XL600 and Electronic spectra of 
the ligand and the complexes were measured in DMF 
using a Jenway 6485 spectrophotometer. 
 
Synthesis of N-phenyl-N'-(2-thiazolyl) thiourea (LH) 
This ligand was prepared using a modified 
literature method25. 
This ligand was prepared by adding Phenyl 
isothiocyanate (1.35 mL, 0.1×10-4 mmol) to a solution 
of 2-aminothiazol (1 g, 0.1×10-4 mmol) in ethanol  
(10 mL). The mixture was heated under reflux for 2 h, 
and then cooled in an ice bath. The formed off-white 
solid was filtered off and washed with ethanol and it 
was recrystallized from ethanol and purified using 
column chromatography (flash chromatography), 
(silica gel 60) and dichloromethane as a solvent. Yield 
88% as off-white crystal; M.p.: 184 °C. Anal.(%) 
calcd. for C10H9N8S2 (235.33): C, 50.99; H, 3.55; N, 4.76. 
Found: C, 50.99; H ,3.55; N, 4.75. IR (ν, cm–1): 3188, 
3325 (NH); 3080 (CHarom.); 1562 (C=N); 1068 (C=S). 
UV-Vis (ν’, cm–1): 29411; 31847 and 38461 (C.T.).1H 
NMR (CDCl3 ppm) δ: 11.03, 12.83 (s, 2H, NH), 6.9–7.7 
(m, 7H, Harom.). 
13C NMR (CDCl3 ppm) δ: 176.91  
(s, (C=S)), 162.17(s, (C=N)), 111.70–137.93 (m, C arom.). 
 
Synthesis of [Pd (L)2] (3)  
This complex was prepared following a modified 
literature method25. To a warm solution of sodium salt 
of the ligand (NaL) [from LH, (200 mg, 0.87 mmol) 
and NaOH, (243 mg, 0.87 mmol)] in EtOH (5 mL) a 
solution of Na2PdCl4 (126 mg, 0.43 mmol) in EtOH 
(5 mL) was added and the solution mixture was 
stirred for 1.5 h. After cooling, a yellow solid was 
formed, filtered, washed with H2O, and recrystallized 
from DMF-EtOH (1:1) and finally dried to give 3. 
Yield (229 mg, 93%) as a yellow solid; M.p.: 255–257 °C. 
Anal.(%) calcd. for C20H16N6PdS4 (575.08): C, 41.73; 
H, 2.78; N, 14.61. Found: C, 41.62; H, 2.90;  
N, 14.71. IR (ν, cm–1): 3299 (NH); 3122, 3057 
(CHarom.); 1595 (C=N); 1030 (C=S); 457 (Pd-S); 540 
(Pd-N). UV-Vis (ν’, cm–1): 30487 (C.T.) and 38461 
(C.T.). 1H NMR ([D6]DMSO ppm) δ: 10.31 (s, 2H, 
NH), 7.67–7.05 (m, 14H, Harom.+ 4-Hthiazole + 5-Hthiazole). 
 
General procedure for the preparation of Pd (II) complexes 4-6 
A solution of bis-(diphenylphosphine)alkane 
Ph2P(CH2)nPPh2 (where n= 1, 2 or 3 ) (0.21 mmol) in 
CHCl3 (5 mL) was heated and added to a warm 
suspension solution of [Pd (L)2] 3 (0.21 mmol) in 
CHCl3 (5 mL) , with the exception for the complex 4 
which was prepared in a mole ratio (2:2) 0.42 mmol. 
The colored mixture stirred for 1.5 h. The solvent was 
evaporated and a mixture of (CH2Cl2-ether) (2:1)  
(5 mL) was added to the residue. The mixture was 
stirred for another hour. A colored solid was formed, 
filtered, and recrystallized from CH2Cl2-EtOH (2:1) 
and dried to give the desired complex. 
 
Preparation of [Pd2 (L)4 (dppm)2] (4)  
From Ph2PCH2PPh2 (162 mg). Yield: (524 mg, 
65%) as orange red solid; M.p.: 125–127 °C. 
Anal.(%) calcd. for C90H76N12P4Pd2S8 (1918.04): C, 
56.31; H, 3.96; N, 8.76. Found: C, 56.02; H, 4.01; N, 




8.90. IR (ν, cm–1): 3300 (NH); 3053 (CHarom.); 2957, 
2928 (CHalph.); 1593 (C=N); 1030 (C=S); 1070 (C-P); 
428 (Pd-P); 351 (Pd-S); 511 (Pd-N). 1H NMR 
([D6]DMSO ppm) δ: 10.31 (s, 2H, NH), 7.79–7.05 
(m, 34H, Harom. + 4-Hthiazole + 5-H thiazole), 3.50 (bs, 2H, 
CH2). 
31P NMR ([D6]DMSO) δP: 16.9 (s) S-bonded 
isomer. UV-Vis (ν’, cm–1): 29761, 38461 (C.T.) 
assigned to the charge transfer transitions n-π*, π–π*, 
respectively of the square planar Pd(II) complex. 
 
Preparation of [Pd (L)2 dppe] (5)  
From Ph2P(CH2)2PPh2 (84 mg). Yield: (125 mg, 
61%) as an orange yellow powder. M.p.: 168–170 °C. 
Anal.(%) calcd. for C46H40N6P2PdS4 (973.5): C, 
56.75; H, 4.11; N, 8.63. Found: C, 56.50; H, 4.06;  
N, 8.87. IR (ν, cm–1): 3380 (NH); 3097, 3055 
(CHarom.); 2955 (CHalph.); 1558 (C=N); 1028 (C=S); 
1070 (C-P); 484 (Pd-P); 327 (Pd-S); 528 (Pd-N).  
1H NMR ([D6] DMSO ppm) δ: 10.20 (s, 2H, NH), 
7.96–6.33 (m, 34H, Harom. + 4-Hthiazole + 5-Hthiazole), 
2.89, 2.73 (t, s-2H, t, s-2H). 31P NMR ([D6]DMSO) δP 
62.6 (d) S-bonded, 54.3 (d) N-bonded (JP-Pd = 40 Hz). 
UV-Vis (ν’, cm–1): 32468, 33003 and 314847 (C.T.), 
attributed to the charge transfer transitions n-π*,π-π* 
or S⟶Pd, P⟶Pd, respectively of the square planar 
Pd (II) complex. 
 
Preparation of [Pd (L)2 dppp] (6) 
Ph2P(CH2)3PPh2 (87 mg). Yield:(114 mg, 55%) an 
orange yellow powder. M.p.: 176–178 °C. Anal.(%) 
calcd. for C47H42N6P2PdS4 (987.50): C, 57.11; H, 4.25; 
N, 8.51. Found: C, 56.89; H, 4.46; N, 8.34. IR (ν, cm–1): 
3356 (NH); 3055 (CHarom.); 2978, 2864 (CHalph.); 1595 
(C=N); 1028 (C=S); 1074 (C-P); 424 (Pd-P); 322  
(Pd-S); 511 (Pd-N). 1H NMR ([D6] DMSO ppm) δ: 
10.23 (s, 2H, NH), 7.94–6.12 (m, 34H, Harom. + 4-Hthiazole 
+ 5-Hthiazole), 2.98, 2.77 (2xq, 4H, P-CH2-CH2-CH2-P), 
1.20 (bs, P-CH2-CH2-CH2-P). 
31P NMR ([D6] DMSO) 
δp: 15.4 (d) N-bonded isomer, 4.2 (d) S-bonded isomer 
(JP-Pd = 140 Hz). UV-Vis (ν’, cm
–1): 21052, 30675 and 
38610 cm-1 (C.T.), assigned to the charge transfer 
transitions n-π*, π-π* or S⟶Pd, P⟶Pd, respectively. 
 
General procedure for the preparation of homo and 
heterobimetallic complexes of Pd(II) with mixed ligands 7-21 
A solid metal chloride MCl2.xH2O (0.35 mmol) 
was added to a solution of [Pd (L)2 Ph2P(CH2)nPPh2] 
{where n = 1 ( dppm ), 2 ( dppe) or 3 ( dppp )}  
(0.35 mmol) in CH2Cl2-EtOH (2:1) (10 mL). The 
mixture was stirred until all the salt was dissolved and 
a colored solution was formed. The resulting solution 
was heated on steam bath until the volume reduced to 
half then left to evaporate at room temperature until a 
solid product was obtained. The solid was extracted 
with CH2Cl2 (10 mL) and the solvent was evaporated 
to dryness to give a colored solid product which was 
recrystallized from CH2Cl2-EtOH (2:1) and dried to 
afford the desired complex. 
 
Preparation of [(dppm) Pd ( µ- L)2 NiCl2(H2O)2] (7) 
From NiCl2.6H2O (84 mg) and complex 4  
(339 mg): Yield: (268 mg, 68%) as a greenish brown 
powder. M.p.: 295 °C dec. Anal.(%) calcd. for 
C45H42Cl2N6NiO2P2PdS4 (1124.71): C, 48.01; H, 3.74; 
N, 7.47. Found: C, 48.19; H, 3.79; N, 7.58. IR  
(ν, cm–1): 3393–3503 (OH); 3301 (NH); 3098, 3050 
(CHarom.); 2928, 2855 (CHalph.); 1533 (C=N); 1028 
(C=S); 1099 (C-P); 478 (Pd-P); 365 (Pd-S); 502  
(Ni-N); 239 (Ni-Cl). 1H NMR ([D6]DMSO ppm) δ: 
10.20 (s, 2H, NH), 7.93–6.85 (m, 34H, Harom. + 4-
Hthiazole + 5-Hthiazole), 1.65 (bs, 2H, P-CH2-P) . UV-Vis 
(ν’, cm–1): 26595 (3A2g (F)→T1g(p)), 27173 (
3A2g 
(F)→T1g (p)) and 30959 (C.T.). 
 
Preparation of [(dppm) Pd (µ- L)2 MnCl2(H2O)2] (8)  
From MnCl2.4H2O (69 mg) and complex 4 (334 mg). 
Yield: (263 mg, 67%) as a nut-yellow powder. M. p.: 
202 °C. Anal.(%) calcd. for C45H42Cl2MnN6O2P2PdS4 
(1120.96): C, 48.17; H,3.75; N, 7.49. Found: C, 48.14; 
H, 3.79; N, 7.53. IR (ν, cm–1): 3474–3500 (OH); 3358 
(NH); 3100, 3058 (CHarom.); 2960, 2827 (CHalph.); 1585 
(C=N); 1028 (C=S); 1072 (C-P); 465 (Pd-P); 365  
(Pd-S); 500 (Mn-N); 247 (Mn-Cl). 1H NMR 
([D6]DMSO ppm) δ: 10.20 (s, 2H, NH), 8.04–7.02  
(m, 34H, Harom. + 4-Hthiazole + 5-Hthiazole), 1.53 (br, 2H,  









Preparation of [(dppm) Pd ( µ- L)2 PdCl2] (9) 
From Na2PdCl4 (103 mg) and complex 4 (336 mg). 
Yield: (322 mg, 81%) as an orange powder. M. p.: 279 
°C dec. Anal.(%) calcd. for C45H38Cl2N6P2Pd2S4 
(1136.44): C, 47.52; H, 3.34; N. 7.39. Found: C, 47.78; 
H, 3.23; N, 7.16. IR (ν, cm–1): 3331 (NH); 3055 
(CHarom.); 2953 (CHalph.); 1566(C=N); 1028 (C=S); 1074 
(C-P); 488 (Pd-P); 308 (Pd-S); 501 (Pd-N); 278 (Pd-Cl). 
1H NMR ([D6]DMSO ppm) δ: 10.20 (s, 2H, NH),  
8.04–7.02 (m, 34H, Harom. + 4-Hthiazole + 5-Hthiazole),  
1.66 (br, 2H, P-CH2-P) . 
31P NMR ([D6]DMSO) δp: 52.3 







Preparation of [(dppm) Pd (µ- L)2 CuCl2(H2O)2] (10)  
From CuCl2.2H2O (60 mg) and complex 4  
(337 mg). Yield: (257 mg, 65%) as a green solid.  




M.p.: 210 °C dec. Anal.(%) calcd. for 
C45H42Cl2CuN6O2P2PdS4 (1129.92): C, 47.79; H,  
3.72; N, 7.43. Found: C, 47.91; H, 4.87; N, 7.29.  
IR (ν, cm–1): 3450b (OH); 3302 (NH); 3121, 3058 
(CHarom.); 2973, 2856 (CHalph.); 1537(C=N); 1027 
(C=S); 1078 (C-P); 500 (Pd-P); 384 (Pd-S); 546  
(Cu-N); 235 (Cu-Cl)). 1H NMR ([D6]DMSO ppm) δ: 
10.20 (s, 2H, NH), 8.04–6.57 (m, 34H, Harom. +  
4-Hthiazole + 5-Hthiazole), 1.70 (br, 2H, P-CH2-P) .  
UV-Vis (ν’, cm–1): 19607 (1B1g→
1Eg) (Cu), 24213 
(1A1g→
1B1g) (Pd), 30581 (C.T), and 39216 (C.T). 
 
Preparation of [(dppm) Pd (µ- L)2 CoCl2(H2O)2] (11)  
From CoCl2.6H2O (83 mg) and complex 4  
(334 mg). Yield: (276 mg, 70%) as a deep green solid. 
M. p.: 185 °C dec. Anal.(%) calcd. for 
C45H42Cl2CoN6O2P2PdS4 (1124.95): C, 48.00; H, 3.73; 
N, 7.47. Found: C, 48.13; H, 3.51; N, 7.58. IR (ν, cm–1): 
3408–3466 (OH); 3350 (NH); 3056 (CHarom.); 2950 
(CHalph.); 1568(C=N); 1028 (C=S); 1074 (C-P); 482 
(Pd-P); 361 (Pd-S); 530 (Co-N); 235 (Co-Cl). UV-Vis 





1Eg) and 33560 (C.T.). 
 
Preparation of [(dppe) Pd ( µ- L)2 NiCl2(H2O)2] (12)  
From NiCl2.6H2O (84 mg) and 5 (344 mg). Yield: 
(283 mg, 71%) as a pale green powder. M. p.: 248 °C. 
Anal.(%) calcd. for C46H44Cl2NiN6O2P2PdS4 
(1139.19): C, 48.46; H, 3.86; N, 7.37. Found: C, 
48.23; H, 3.60; N, 7.08. IR (ν, cm–1): 3427 (OH); 
3360 (NH); 3098, 3058 (CHarom.); 2928, 2858 
(CHalph.); 1586 (C=N); 1026 (C=S); 1078 (C-P); 482 
(Pd-P); 368 (Pd-S); 529 (Pd-N); 278 (Ni-Cl). UV-Vis 
(ν’, cm–1): 25000 (3A2g(F)→T1g(p)), 29411 
(1A1g(F)→
1Eg(p)) and 39683 (C.T.). 
 
Preparation of [(dppe) Pd ( µ- L)2 MnCl2(H2O)2] (13) 
From MnCl2.4H2O (69 mg) and complex 5  
(339 mg). Yield: (238 mg, 60%) as a pale yellow.  
M.p.: 170 °C. Anal.(%) calcd. for 
C46H44Cl2MnN6O2P2PdS4 (1135.44): C, 48.62; H, 
3.88; N, 7.40. Found: C, 48.74; H, 3.99; N, 7.33. IR 
(ν, cm–1): 3414 (OH); 3332 (NH); 3055 (CHarom.); 
2950 (CHalph.); 1595 (C=N); 1028 (C=S); 1074 (C-P); 
484 (Pd-P); 368 (Pd-S); 530 (Pd-N); 245 (Mn-Cl). 
UV-Vis (ν’, cm–1): 25000 (1A1g→
1B1g), 29940 
(6A1g→
4T2g (4D)), 30487 (C.T.) and 30959 (C.T.). 
 
Preparation of [(dppe) Pd (µ- L)2 PdCl2] (I4)  
From Na2PdCl4 (103 mg) and complex 5 (341 mg). 
Yield: (306 mg, 76%) as a brown powder. M.p.:  
220 °C dec. Anal.(%) calcd. for C46H40Cl2N6P2 Pd2S4 
(1150.92): C, 47.96; H, 3.48; N, 7.30. Found: C, 
47.82; H, 3.21; N, 7.18. IR (ν, cm–1): 3365 (NH); 
3126, 3056 (CHarom.); 2950 (CHalph.); 1558 (C=N); 
1028 (C=S); 1074 (C-P); 488 (Pd-P); 338 (Pd-S); 530 
(Pd-N); 280 (Pd-Cl). 1H NMR ([D6]DMSO ppm)  
δ: 10.51 (s, 2H, NH), 8.14–6.99 (m, 34H, Harom. +  
4-Hthiazolee + 5-Hthiazolee), 2.92, 2.76 (2xbs, 4H, dppe). 
31P NMR ([D6] DMSO) δp: 66.6 (s, P-Pd) S-bonded 
isomer. UV-Vis (ν’, cm–1): 28212 (1A1g→
1Eg), 
37878, and 41000 are attributed to C.T. respectively.  
 
Preparation of [(dppm) Pd (µ- L)2 CuCl2(H2O)2] (15) 
From CuCl2.2H2O (60 mg) and complex 5  
(343 mg). Yield: (248 mg, 62%) as a green solid.  
M.p.: 146 °C. Anal.(%) calcd. for 
C46H44Cl2CuN6O2P2PdS4 (1144.05): C, 48.25; H, 
3.85; N, 7.34. Found: C, 48.13; H, 3.61; N, 7.17. IR 
(ν, cm–1): 3490 b (OH); 3350 (NH); 3055 (CH arom.); 
2914 (CH alph.); 1560(C=N); 1029 (C=S); 1073 (C-P); 
484 (Pd-P); 343 (Pd-S); 530 (Pd-N); 270 (Cu-Cl). 
UV-Vis (ν’, cm–1): 27110 (1A1g →
1Eg), 28571 
(1A1g→ 
1B1g), 32787 (C.T), and 43860 (C.T). 
 
Preparation of [(dppe) Pd (µ- L)2 CoCl2(H2O)2] (16) 
From CoCl2.6H2O (83 mg) and complex 5  
(334 mg). Yield: (271 mg, 68%) as a deep green 
powder. M.p.: 231 °C dec. Anal.(%) calcd. for 
C46H44Cl2CoN6O2P2PdS4 (1139.43): C, 48.45;  
H, 3.86; N, 7.37. Found: C, 48. 31; H, 4.01; N, 7.59. 
IR (ν, cm–1): 3408–3466 (OH); 3345 (NH); 3056 
(CHarom.); 2960 (CHalph.); 1568 (C=N); 1028 (C=S); 
1074 (C-P); 482 (Pd-P); 361 (Pd-S); 530 (Pd-N);  
235 (Co-Cl). 1H NMR ([D6]DMSO ppm) δ: 10.51  
(s, 2H, NH), 8.15–6.99 (m, 34H, Harom. + 4-Hthiazolee + 
5-Hthiazolee), 2.77, 2.62 (2xbs, 4H, dppe) . UV-Vis  
(ν’, cm–1): 21186 (4T1g (F) →




Preparation of [(dppp) Pd ( µ- L)2 NiCl2(H2O)2] (17) 
From NiCl2.6H2O (84 mg) and complex 6  
(349 mg). Yield: (275 mg, 68%) as a pale green 
powder. M.p.: 217 °C dec. Anal.(%) calcd.  
for C47H46Cl2NiN6O2P2PdS4 (1153.21): C, 48.91; H, 
3.99; N, 7.28. Found: C, 48.86; H, 3.86; N, 7.14. IR 
(ν, cm–1): 3447 (OH); 3297 (NH); 3065 (CHarom.); 
2960–2860 (CHalph.); 1524 (C=N); 1028 (C=S); 1074 
(C-P); 482 (Pd-P); 372 (Pd-S); 572 (Pd-N); 278  
(Ni-Cl). UV-Vis (ν’, cm–1): 28169(3A2g→ T1g(p)), 
29411 (1A1g→ 
1Eg), 37878 (C.T.). 
 
Preparation of [(dppp) Pd ( µ- L)2 MnCl2(H2O)2] (18) 
From MnCl2.4H2O (69 mg) and complex 6  
(344 mg). Yield: (314 mg, 78%) as a yellow  
powder. M.p.: 248 °C. Anal.(%) calcd. for 




C47H46Cl2MnN6O2P2PdS4 (1149.46): C, 49.07; H, 
4.00; N, 7.31. Found: C, 48.97; H, 4.05; N, 7.25. IR 
(ν, cm–1): 3400–3550 (OH); 3363 (NH); 3055 
(CHarom.); 2950 (CHalph.); 1540 (C=N); 1028 (C=S); 
1072 (C-P); 444 (Pd-P); 343 (Pd-S); 509 (Pd-N); 235 




4D)) and 30959 (C.T.). 
 
Preparation of [(dppp) Pd ( µ- L)2 PdCl2] (19) 
From Na2PdCl4 (103 mg) and complex 6 (346 mg). 
Yield: (294 mg, 72%) as a reddish orange. M.p.:  
198 °C dec. Anal.(%) calcd. for C47H42Cl2N6P2Pd2S4 
(1164.94): C, 48.41; H, 3.61; N, 7.21. Found: C, 
48.59; H, 3.82; N, 7.11. IR (ν, cm–1): 3410 (NH); 
3078 (CHarom.); 2900 (CHalph.); 1562 (C=N); 1030 
(C=S); 1072 (C-P); 451 (Pd-P); 363 (Pd-S); 513  
(Pd-N); 241 (Pd-Cl). 1H NMR ([D6]DMSO ppm) δ: 
10.52 (s, 2H, NH), 8.14-7.00 (m, 34H, Harom. +  
4-Hthiazolee + 5-Hthiazolee), 2.82, 2.68 (2xq, 4H, dppp), 
1.48 (bs, 2H, dppp). 31P NMR ([D6] DMSO) δp: 12.53 
(s, P-Pd) S-bonded isomer. UV-Vis (ν’, cm–1): 
28571(1A1g→
1Eg), 37878 (C.T.) and 40000 (C.T.). 
 
Preparation of [(dppp) Pd ( µ- L)2 CuCl2(H2O)2] (20) 
From CuCl2.2H2O (60 mg) and complex 6  
(348 mg). Yield: (324 mg, 80%) as a deep green solid. 
M.p.: 148–150 °C. Anal.(%) calcd. for 
C47H46Cl2CuN6O2P2PdS4 (1158.07): C, 48.70; H, 
3.97; N, 7.25. Found: C, 48.53; H, 3.89; N, 7.17. IR 
(ν, cm–1): 3492–3500 (OH); 3350 (NH); 3055 
(CHarom.); 2925 (CHalph.); 1543(C=N); 1026 (C=S); 
1069 (C-P); 430 (Pd-P); 359 (Pd-S); 511 (Pd-N); 235 
(Cu-Cl). 1H NMR ([D6] DMSO ppm) δ: 10.22 (s, 2H, 
NH), 7.88–6.11 (m, 34H, Harom. + 4-Hthiazolee +  
5-Hthiazolee), 2.82, 2.68 (2xq, 4H, dppp), 1.77 (bs, 2H, 
dppp). UV-Vis (ν’, cm–1): =22727 (1B1g→
1Eg)), 
27473 (1A1g→
1B1g), 28329 (C.T.) and 30581 (C.T.).  
 
Preparation of [(dppp) Pd (µ- L)2 CoCl2(H2O)2] (21) 
From CoCl2.6H2O (83 mg) and complex 6  
(344 mg). Yield: (283 mg, 70%) as a deep green 
powder. M.p.: 169 °C, dec. Anal.(%) calcd. for 
C47H46Cl2CoN6O2P2PdS4 (1153.45): C, 48.90; H, 
3.99; N, 7.28. Found: C, 49.08; H, 4.02; N, 7.42. IR 
(ν, cm–1): 3450 (OH); 3350 (NH); 3120, 3055 
(CHarom.); 2927 (CHalph.); 1595(C=N); 1028 (C=S); 
1078 (C-P); 499 (Pd-P); 383 (Pd-S); 586 (Pd-N); 245 







In vitro cytotoxicity assessment  
The cytotoxic activity of the NCD was evaluated 
against RMS cell line using the MTT assay49. These 
cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplement with 10% heat 
inactivated fetal bovine serum (FBS). In order to 
maintain the cells in an exponential phase cellular 
suspension, aliquots were replenished with fresh 
DMEM two or three times per week. Cells were 
inoculated in 96-well microtiter plate (105 cells/well) 
for 48 h to allow growth of cell monolayer to the wall 
of the microtiter plate. The optimization protocol was 
achieved for the toxicity screening of compounds to 
the cell monolayer. The tested compounds were 
freshly resolved in DMSO and diluted in DMEM 
consequently. The final concentration of the solvent 
never exceeded than 0.1%. Triplicates were prepared 
for each individual dose. Monolayer cells were 
incubated with the target compounds for 24 h, at  
37 °C, 5% CO2 and incubated at 37 °C in a 
humidified atmosphere. Color intensity was measured 
in an ELISA reader. The viability and inhibition % of 
cancer cell line after the specified time were then 
detected.  
 
Results and Discussion 
The ligand N-phenyl-N'-(2-thiazolyl) thiourea (LH) 
was prepared by reaction of phenyl isothiocyanate 
with 2- aminothiazol in 86% yield, following our 
modified literature method25. Sodium salt of 
deprotonated ligand (LH) was reacted with sodium 
tetrachloro palladate(II) (Na2PdCl4) (2:1 molar ratio) 
to give PdL2 3 in 93% yield. (Scheme1). The 
1H and 
13C NMR spectroscopy and other physical properties 
of the ligand (LH) and complex PdL2 3 were identical 
with the authentic samples prepared previously in our 
laboratory25. Treatment of 3 with Ph2P(CH2)nPPh2  
(n = 1, 2, or 3) afforded the mixed ligand complexes 
4-6 in 65, 61 and 55 % yield, respectively. 
The structures of 4-6 were identified using 
elemental analysis, IR, 31P-{1H}-and 1H-{31P} NMR 
spectra, and also from spectral comparison with the 
ligand (LH) as well as with complex 3 (which have 
been synthesized previously25) and other 
complexes26,27. The 31P-{1H} NMR data have been 
used effectively to identify the produced linkage 
isomers (Scheme 1). The IR spectra of 4-6 showed 
bands between 1028–1030 cm-1 1558–1595 cm-1 
assigned to ν (C=S) and ν(C=N) of thiazole backbone 
(L), respectively27. The strong bands at the range 
511–540 cm-1, and the medium intensity bands at 
322–351 cm-1 were attributed to ν(Pd-N), and ν(Pd-S), 
respectively28 which confirmed coordination of the 
ligands  through  their  nitrogen  and  thioamide sulfur 






Syntheses of the ligand (LH) and some Pd (II) mononuclear, homo and heterobimetallic mixed ligand complexes 3-21 
 
Scheme 1 




atoms. Further, the two bands appeared at the ranges 
1070–1074 cm-1, and 428–484 cm-1 were assigned to 
ν(C-P) and ν(Pd-P), respectively29-31, which still 
confirmed the coordination of diphosphine ligands to 
the Pd(II) ions. The 31P{1H} NMR spectrum of 4 
showed a signal at δP = 16.93 ppm. The positive 
chemical shift value of this signal indicated that the 
dppm ligand behaved as a bidentate bridging ligand32, 
while a single peak denoted to one isomeric form of 
this complex with indication that the ligands L are  
S-bonded to the Pd(II) ion. The 31P-{1H} NMR 
spectra of 5 and 6 showed two doublets at δP = 62.64, 
54.29 ppm (2J = 40 Hz) and δP = 15.45, 4.18 ppm 
(2JP,P =140 Hz). The coupling between the two 
doublets indicated the presence of a single isomer 
with two different phosphorus atoms; one was  
trans to sulfur atom while the other was trans to 
nitrogen atom29,30. The 1H-{31P} NMR spectra of 
 4, 5 and 6 showed broad signals at the regions  
δ = 8.42-6.32 ppm assigned to the two aromatic protons 
of the ligands, while the singlet at δ = 10.18 ppm 
assigned to the ligand NH. The resonance at δ = 3.60 ppm 
was attributed to methylene protons of the dppm 
group of 4, while the two triplets at δ = 2.70 and  
2.90 ppm were assigned to two methylene protons of 
the dppe moiety of 5. The multiplet and quartet at  
δ = 1.20 (2H) and 2.90 ppm (4H) were assigned to 
three methylene protons of the dppp group of 
complex 6. Elemental analyses, molar conductivity and 
magnetic susceptibility measurement are additional 
support for the formation of the complexes 4-6.  
 
Next, the complexes 4-6 were treated with salts of 
Ni (II), Cu (II), Mn (II), Co (II) and Pd (II) in 
refluxing EtOH to give the homo- and 
heterobimetallic complexes 7-21 in 60–81% yield 
(Scheme 1). Characterization of these complexes was 
carried out using elemental analysis, molar 
conductivity, magnetic susceptibility measurements 
UV-Vis, FT-IR, 31P-{1H} NMR and 1H-{31P} NMR 
spectroscopy. The UV-Vis spectrum of complex 3 
showed two bands at 30487, and 38461 cm-1 assigned 
to the ligand charge transfer transitions; n-𝜋 ∗ and  
𝜋-𝜋 ∗ .respectively. In the IR spectra, the ν(C=N) of 
the ligand at 1627 cm-1 is found to be shifted to a 
lower energies between 32–34 cm-1 in the spectra of 
the complexes 8, 11, 12 and 21, indicating 
coordination via the azomethine nitrogen of the 
thiazole backbone. Major shifts of the ν(C= N), 
around 32–94 cm-1 , were observed as well in the IR 
spectra of 7, 9, 10, 11 and 13-21 indicative of 
chelation of N atoms of the thiazole ligand to the 
metal ions. Additionally, the complexes 7-21 (except 
9, 14 and 19) exhibited a broad band in the range of 
3400–3500 cm-1 assigned to the lattice water, whereas 
the absence of such IR broad band in Pd(II) 
complexes 9, 14 and 19 is in agreement with the 
analytical data, where water molecules do not exist. 
The position of the (C=S) band in the complexes 3-21 
is around 1028 cm-1 which is changed significantly in 
comparison to the free ligand LH (~1068 cm-1) 
indicating coordination of the thioamide group to the 
metal ions through its S atom. A medium intensity 
band in the range 1072–1099 cm-1 was attributed to 
ν(C-P), while a strong band at 444–503 cm-1 assigned 
to ν (Pd-P). Furthermore, the IR spectra of 7-21 showed 
a medium intensity band at around 500–550 cm-1 
assigned to ν (M-N), while a band in the range  
308–385 cm-1 referred to the ν (Pd-S) of the prepared 
complexes. The IR spectra of the new complexes 
(except 9, 14 and 19) showed strong intensity bands 
in the range 240–293 cm-1 assigned to ν (M-Cl,  
M = Ni, Mn, Cu, Co) suggesting a cis arrangement of 
the chlorine atoms32. Complexes 9, 14 and 19 exhibited 
medium intensity bands between 235–293 cm-1 assigned 
to ν(Pd-Cl) in a cis arrangement, which are in 
agreement with the reported values27,18,33. The 1H 
NMR spectra of 7-21 showed multiplets in the regions 
δ = 6.11–8.14 ppm assigned to the aromatic protons 
together with 4-H and 5-H of the thiazole rings.The 
methylene groups of diphenylphosphine residues were 
fully analyzed (c.f. Experimental section). 
The 31P-{1H}NMR spectra of 9, 14 and 19 showed 
a sharp singlet at δP = – 52.3, 66.6 and 12.53 ppm 
respectively, indicated the formation of single isomers 
where the ligands coordinated to Pd(II) ion through 
the thioamide and thiazole sulfur atoms (S-bonded 
isomers), and are in a good agreement with the 
reported values34. 
 
Magnetic susceptibility measurements 
The electronic spectral measurements were used 
for assigning the stereochemistry of metal ions in the 
complexes based on the positions and number of d -d 
transition peak. Magnetic susceptibility measurements 
obtained at room temperature for complexes 7, 8,  
10-13, 15-18, 20 and 21 are listed in Table 1, and they 
were found to be paramagnetic in nature, while, 9, 14 
and 19 were diamagnetic. For Ni(II) in complexes 7, 
12 and 17, the observed magnetic moment values 
(µeff =3.65, 3.18 and 3.16 BM) respectively35, which 
are in well agreement with the expected range for 




Ni(II) complexes with octahedral stereochemistries 
2.83 BM. The observed magnetic moment for Mn(II) 
in complexes 8, 13, and 18 are 5.67, 5.63 and 6.10 
BM respectively, suggested octahedral arrangements 
around Mn(II) ions in these complexes (theoretical 
µeff = 5.92 BM)36. The observed magnetic moment 
for the Cu (II) in complexes 10, 15 and 20 are 1.93, 
2.02 and 2.10 BM, respectively. The observed values 
(1.73 BM) are slightly higher than the spin-only value 
due to one unpaired electron and suggesting 
octahedral geometry37. Thus, the present Cu(II) 
complex is devoid of any spin interaction with 
distorted octahedral geometry. In the present 
investigation the observed magnetic moment values 
of the Co(II) in complexes 11, 16 and 21 are 3.99, 
4.04 and 4.51 BM, which indicates octahedral 
geometry for the Co(II) in these complexes 
(theoretical µeff = 3.88 BM). Magnetic susceptibility 
values for the complexes 9, 14 and 19 are zero which 
suggests a square planar geometry around Pd (II) 
ions38. In conclusion, in all the prepared complexes  
3-21, Pd (II) ion has a square planar geometry while 
the metal ions Ni (II), Mn(II), Co(II) and Cu(II) have 
octahedral geometries. The complexes 3-21 are 
considered as non-electrolytes39since their molar 
conductivity values fall in the range 0–2.702 Ω-1 cm2 
mol-1 in dimethyl formamide (DMF) , which are 




In vitro inhibition activity of rhabdomyosarcoma (RMS) 
Rhabdomyosarcoma (RMS) is a malignancy that 
arises from skeletal muscle that have failed to fully 
differentiate40,41. It is the most common type of soft 
tissue sarcoma in children and adolescents, less than 
20 years old. Rhabdomyosarcomas are highly 
chemosensitive, with approximately 80% of cases 
responding to chemotherapy and the combination of 
anticancer drugs: vincristin, actinomyocin D and 
cyclophosphamide (VAC) remained the standard 
chemotherapy in North America for nonmetastatic 
RMS42. Few laboratories have reported the synthesis of 
various analogs aiming to evaluate their cytotoxicity 
against Rhabdomyosarcoma cell line43-47. Al-Asady  
et al.,48 have reported the cytotoxicity and cytogenetic 
effects of crude extract of Nicotiana on RMS and 
LB20B cell lines at different concentrations. Some 
synthesized complexes been selected to evaluate their 
inhibitory activity against rhabdomyosarcoma (RMS) 
cell line at different concentrations (500, 250,  
125 μg/mL) for 48 h, using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) 
method49. The results are summarized in Table 2, in 
which the data for the ligand (LH) is included for 
comparison purposes. The effect of the selected 
complexes on autocrine growth of rhabdomyosarcoma 
(RMS) human malignancies is shown in Fig. 2.  
The figure summarizes growth inhibition (%) obtained 
by MTT method. The cytotoxicity of these complexes 
are devoid of anticancer activity since their (%) of 
Table 1 — Magnetic susceptibility and molar conductivity of the 
complexes 3-21 in DMF 








3   13 27.02 5.63(5.92) 
4   14 9.98 0 
5   15 23.90 2.02(1.73) 
6   16 8.45 4.04(3.88) 
7 3.07 3.65 17 2.70 3.16(2.83) 
8 26.97 5.67(5.92) 18 26.98 6.10(5.92) 
9 9.23 0 19 9.49 0 
10 22.06 1.93(1.73) 20 25.1 2.10(1.73) 
11 8.32 3.99(3.88) 21 8.10 4.51(3.88) 
12 2.80 3.18(2.83)  
 
Table 2 — Cytotoxicity effect of some Pd(II) and metal ions 
complexes on RMS cells line 
        Compd. % of RMS growth inhibition 
 500 µg/mL 250 µg/mL 125 µg/mL 
LH 12.0 20.0 9.0 
3 30.0 44.0 7.0 
4 32.0 43.0 8.0 
5 18.0 40.0 17.0 
10 40.0 42.0 0.0 
13 38.0 48.0 6.0 
15 41.0 5.0 6.5 
16 38.0 5.0 7.0 
19 25.0 90.0 5.0 
20 12.0 28.0 39.0 




Fig. 2 ⸺ The growth inhibition of RMS cancer cell line by some 
Pd(II) and metal ion complexes determined by MTT test after 48 
h at different concentrations. 
 




RMS growth inhibition is less than 50%, except Pd(II) 
complex 19 which exhibited significant inhibition 
activity for RMS cell line (90%) at 250 µg/mL.  
In conclusion, the structure-activity relationship 
(SAR) suggested that the potency of complex 19 
could be attributed to the presence of the two 
palladium (II) atoms coordinated with the thioamide 
and thiazole moieties via their sulfur atoms. 
Therefore, complex 19 can be considered as a 
promising agent for treatment of human 




In this work, N-phenyl-N'-(2-thiazolyl) thiourea 
(LH) and its complexes were screened for their  
In vitro antimicrobial activity against the two 
microbial isolates. The antimicrobial activities of the 
compounds were tested by the agar disc-diffusion 
method. The starting ligand N-phenyl-N'-(2-thiazolyl) 
thiourea (LH) as well as its some metal complexes 
showed no antimicrobial activity. However, 
complexes 5, 10, 13, 18 and 20 were highly sensitive 
against Staphylococcus aureus bacterium while the 
same complexes showed resistance against 
Escherichia coli bacterium. On the other hand, 
complexes 3, 8 and 9 showed resistance against both 
bacteria. 
Generally, from antibacterial data of these 
complexes, we have observed that the synthesized 
complexes are sensitive or resistant due to the 
lipophilic character of the metal ion in the complexes 
which can be increased or decreased upon chelation 
with the free ligands and make the bacterial 
membrane to be permeable or non-permeable 
respectively for these complexes through the lipoid 
layer of the bacteria organisms. In addition, 
stereochemistry of these complexes plays important 
role in the antimicrobial activity which could improve 
their binding with amino acid of S. auereus. 
Factors such as solubility, conductivity, electron 
density, the molecular size and stereochemistry of the 
complexes, permeability of organism membrane and 
the concentration have influence on the activity 
progress of the synthesized complexes. 
 
Molecular modeling analysis 
Seitz et al.,50 reported that inhibition of 
glutathione-S-transferase (GST) would lead for a 
treatment strategy for multidrug resistance in 
childhood rhabdomyosarcoma (RMS), since the 
highest induction of GST activity was found in 
embryonal RMS (up to 12-fold). In accordance to 
Seitz and co-workers, we decided to study the 
modeling analysis of one of the GST protein codes 
with the most active inhibitors of RMS cell lines 
(compound 19). Our molecular docking analysis is 
based on the modeling studies to understand the 
binding mode of this analogue with the GST binding 
pockets.  
Glutathione S-transferases (GSTs) comprise a 
family of detoxification enzymes that catalyze the 
conjugation of glutathione with carcinogens, drugs, 
toxins and products of oxidative stress. It is believed 
that the function of these enzymes is to reduce the 
incidence of deleterious interactions between reactive 
toxic species and cellular components. Glutathione  
S-transferases have been implicated in the 
development of resistance to cancer chemotherapeutic 
agents. High levels of GST expression have been 
reported in a number of tumors compared to normal 
tissues. GST has many PDB codes like: 5YVN, 
6ATO, 6EZY, 6AP9, 6ATP. The binding energy 
score (kcal/mol) and root mean square deviation 
(RMSD) are important parameters in prediction of the 
selective and potency profiles of the ligand to bind the 
active site of GST pocket. Generally, RMSD values 
representation mainly for analysing the stability of 
protein and predicting conformational changes of 
protein RMSD values depends upon the binding 
interaction and energy between protein and ligand. 
The optimized protein has lowest RMDS values 
(ideally less than 1.5 Å, or even better, less than 1 Å). 
In this case a low RMSD with respect to the  
true binding pose is good51. This represents  
good reproduction of the correct pose. GST with 
(PBD ID 5YVN)52 has a lowest binding energy score 
(–7.589 kcal/mol) in comparison to the other codes 
(as shows in Table 3), with acceptable RMSD value 
(1.296 Å , which is under the expected range of < 2 Å 
therefore PBD ID 5YNV of GST has been selected 
for our molecular docking study. 
The molecular docking was performed using the 
Molecular Operating Environment 2016 (MOE 2016) 
Table 3 — The S and RMSD values of GTS PBSs docking with 19 
Protein Sa RMSDb 
5YVN –7.589 1.296 
6ATO –6.923 1.246 
6EZY –5.765 2.517 
6AP9 –6.538 1.951 
6ATP –6.534 1.519 




software and the docking results were also shown by 
MOE53. Compound 19 has been selected to show its 
binding to the enzyme pocket (Fig. 3). As shown in  
Fig. 3a, the aromatic ring of thiourea group of 19 fitted 
into an arene-rich subpocket surrounded by the aromatic 
side chain of Phe31. Detailed analysis of the binding 
mode showed that the aromatic rings point toward the 
aromatic ring Phe31 residue apparently developing π-π 
stacking interaction with 19 phenyl group. The thiazole 
backbones as well as the triphenylphosphine groups are 
located in the middle of the binding pocket, anchoring 
the N-phenylthiourea substituent at thiazole moiety in a 
favorable position for hydrophobic interactions with 
other substituents of 19. Overall, the combination of 
hydrophobic interaction and π-π stacking appears to 
govern the binding of 19 with GST amino acid residues. 
In conclusion, the presence of two Pd(II) atoms and 
bis(diphenylphosphino) propane, dppp gives flexibility 
to molecule to locate properly in the active site of the 
amino acids pocket of GST (PBD ID 5YVN). The 3D 
interaction of 19 with amino acid residue (Phe31) of 
GST is shown in Fig. 3b. 
 
Conclusions 
A new series of the Pd(II) complexes with some 
transition metals containing the ligands N-phenyl-N'-
(2-thiazolyl)thiourea and diphenylphosphines have 
been prepared 4-21. In the complex 4, dppm behaved 
as a bridged ligand while in other complexes its 
behaved as a chelate ligand but the dppe and dppp 
behaved as chelate ligands in their complexes. 
Some new complexes were assayed for their 
inhibition activity against human rhabdomyosarcoma 
(RMS) cell line and found that 19 exhibited a 
significant cytotoxicity inhibition activity ~90% for 
RMS cell line, suggesting to be a new lead in the 
development of human muscle anticancer agent. All 
complexes have been assayed for their antibacterial 
activity and complexes 5, 10, 13, 18 and 20 exhibited a 
highly sensitive inhibition activity against S. aureus 
bacterium while revealed a resistance against E. coli 
bacterium. The other complexes showed no activity. 
The Modeling calculations of 19 have given significant 
information for improving the biological activity of the 
new synthesized complexes. The docking study of 19 
showed a pi-pi interaction with Phe31 of GST. 
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